血清和胸腔积液中CEA、Fer、NSE和SCC联检对肺癌诊断价值的探讨

目的：探讨血清和胸腔积液中的肿瘤标志物CEA、Fer、NSE和SCC联检诊断肺癌的临床价值。方法：采用放射免疫分析和化学发光免疫分析了52例肺癌、48例肺良性疾病血清和胸腔积液的肿瘤标志物CEA、Fer、NSE和SCC水平，并与正常对照组进行了对比。结果：52例肺癌血清和胸腔积液中的肿瘤标志物CEA、Fer、NSE和SCC水平明显高于48例肺良性疾病患者（P值均〈0．01）和正常对照组（P值分别为〈0．001，〈0．001，〈0．01和〈0．01）。血清和胸腔积液中的肿瘤标志物CEA、Fer、NSE和SCC的联检诊断肺癌的阳性率高于92．7％。结论：血清和胸腔积液中的肿瘤标志物CEA、Fer、NSE和SCC的联检是诊断肺癌的好方法。

Combined Determination of CEA,Fer,NSE and SCC Levels in Serum and Chest Effusion Fluid For Diagnosis of Pulmonary Cancer

Objective To study the clinical value of combined determination of CEA,Fer,NSE and SCC levels in serum and chest effusion fluid for dignosis of lung cancer.Methods These four tumor markers were determined in serum and chest effusion fluid with RIA(NSE and SCC) or chemiluminescence method(CEA and Fer) in 52 patients with lung cancer,48 patients with benign lung disease and 51 controls.Results The serum and chest effusion fluid levels of CEA,Fer,NSE and SCC in patients with lung cancer were significantly higher than those in patients with benign lung diseases(all P<0.01) and 51 controls(P<0.001,<0.001,<0.01 and <0.01 respectively).The positive rate of combined determination of CEA, Fer,NSE and SCC for lung cancer could be above 92.7%.Conclusion Combined determination of CEA,Fer,NSE and SCC were a useful method for lung cancer diagnosis.